<DOC>
	<DOCNO>NCT02720224</DOCNO>
	<brief_summary>This study conduct understand elimination pathway , metabolite profile pharmacokinetic ( PK ) profile carbon 14 label estetrol ( [ 14C ] estetrol ) .</brief_summary>
	<brief_title>Study Conducted Further Understand Elimination Pathways , Metabolite Profile PK Profile 14C-estetrol</brief_title>
	<detailed_description>This open-label , non-randomised , single dose study healthy female volunteer non-child bearing potential . Subjects screen eligibility participate study 28 day dose . The study execute single group , 6 subject enrol dosed single oral dose carbon 14 label estetrol . Subjects admit clinical unit morning prior study drug administration ( Day -1 ) . Dosing take place morning Day 1 overnight fast ( approximately 10 h ) . Subjects resident clinic 240 h dose plasma , blood , urine faeces sample collect . It plan subject release group subject achieve mass balance cumulative recovery &gt; 90 % mean &lt; 1 % dose administer collected urine faeces within 2 separate , consecutive 24 h period . In case , collection sample ( blood , urine faeces ) stop subject undergo discharge assessment . If criterion meet subject Day 11 , home collection urine faeces may request discretion investigator individual subject .</detailed_description>
	<criteria>1 . Healthy female nonchild bear potential , i.e . surgically sterilise post menopausal subject . Postmenopausal status define absence menses minimum 12 month confirm FSH result ≥30 IU/ml 2 . Negative pregnancy test screen Day 1 3 . 30 65 year age inclusive 4 . Body mass index ≥18.0 ≤30.0 kg/m2 5 . Must willing able communicate participate whole study 6 . Must provide write informed consent 7 . Must regular bowel movement ( i.e . average stool production ≥1 ≤3 stool per day ) Must agree use adequate method contraception 1 . Participation clinical research study within previous 3 month 2 . Subjects study site employee , immediate family member study site sponsor employee 3 . Subjects previously enrol study 4 . History drug alcohol abuse past 2 year 5 . Regular alcohol consumption i.e . &gt; 14 unit per week ( 1 unit = ½ pint beer , 25 ml 40 % spirit 125 ml glass wine ) 6 . Current smoker smoke within last 12 month . A breath carbon monoxide read great 10 ppm screen 7 . Females pregnant lactate 8 . Radiation exposure , include present study , exclude background radiation include diagnostic xrays medical exposure , exceed 5 mSv last 12 month 10 mSv last 5 year . No occupationally expose worker , define Ionising Radiation Regulations 1999 , shall participate study 9 . Subjects suitable vein multiple venepunctures/cannulation assess screen 10 . Clinically significant abnormal biochemistry , haematology urinalysis judge investigator 11 . Positive drug abuse test result 12 . Positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( HCV Ab ) human immunodeficiency virus ( HIV ) result 13 . History presence clinically significant cardiovascular , renal , hepatic , chronic respiratory gastrointestinal disease judge investigator 14 . Serious adverse reaction serious hypersensitivity drug formulation excipients 15 . Presence history clinically significant allergy require treatment , judge investigator . Hayfever allow unless active 16 . Donation loss great 400 ml blood within previous 3 month 17 . Subjects take , take , prescribed medication 28 day IMP administration ( exception may apply case case basis provide consider interfere objective study agree PI delegate sponsor 's medical monitor ) , overthecounter drug herbal remedy 14 day IMP administration . If need ( i.e . incidental limit need ) ibuprofen acceptable analgesic treatment , must document ( Case Report Form ) CRF . Use paracetamol forbidden entire study 18 . Subjects euthyroid condition ( thyroidstimulating hormone [ TSH ] free thyroxine [ fT4 ] within normal reference range ) 19 . Any history suspect malignancy exception basal cell ( exclude within prior 2 year ) squamous cell ( exclude within prior one year ) carcinoma skin 20 . History presence prolong QT interval correct Bazett 's formula clinically significant ECG abnormality judge investigator base 12lead ECG reading screen 21 . Subjects abnormal supine blood pressure screening : least 2 reading systolic blood pressure great 140 mmHg low 90 mmHg , and/or diastolic blood pressure 90 mmHg low 50 mmHg minimum interval 5 min 22 . Any surgical medical condition might significantly alter absorption , distribution , metabolism , excretion drug , may jeopardize subject case participation study . The investigator make determination consideration subject 's medical history and/or clinical laboratory evidence follow : History symptom inflammatory bowel disease , gastritis , ulcer , gastrointestinal rectal bleeding , History major gastrointestinal tract surgery ( subject appendectomy acceptable inclusion ) , History presence pancreatic injury pancreatitis , History presence impair hepatic function , History presence liver disease liver injury indicate abnormal liver function test aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , gammaglutamyl transferase ( GGT ) , alkaline phosphatase ( ALP ) , total serum bilirubin . Any single parameter elevate ≥1.5 fold upper limit normal rechecked prior enrolment/randomisation ( subject cholecystectomy acceptable inclusion liver/gallbladder parameter normal range ) , History presence impair renal function consider clinically significant , Abnormal urinary constituent ( e.g . albumin consider clinically significant ) . 23 . Suspected current history gynaecological breast pathology , include abnormal Pap smear within 3 previous year ( ASCUS , ASCH , LGSIL bad ) history abnormal mammogram within 2 previous year 24 . Failure satisfy investigator fitness participate reason</criteria>
	<gender>Female</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>